Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Maxigen Biotech Inc. (1783.TW)
Taoyuan City, TW
Maxigen Biotech Inc. (MBI) is a company dedicated to the research, development, production, and global commercialization of advanced biomedical and skincare solutions. Its extensive biomedical portfolio includes various orthopedic products such as Formagraft, a bone graft substitute, and Formasetin, a bone void filler. For intra-articular applications in orthopedics, MBI markets injections under the names ArtiAid, ArtiAid Plus, and ArtiBest. The company's offerings also span both orthopedic and dental fields, featuring Foramic, a bone substitute granule; MaxiBone, a calcium phosphate ceramic; and GingivAid, a collagen dental graft. Specifically for dental use, MBI provides FormaAid, a collagen membrane, and the E-TECH DENTISTAR II sterilizer and disinfectant. Furthermore, HealiAid, a collagen wound dressing product, serves dental and general wound care purposes. MBI also manufactures ophthalmic viscoelastic devices, known as ViscAid, PreviscAid, and BiVisc, and produces Formaderm, a dermal filler injection utilized in plastic surgery. Beyond its medical devices, Maxigen Biotech Inc. offers a comprehensive line of skincare products. This array includes masks for the face, neck, body, and limbs, alongside make-up removers, cleansers, exfoliants, toners, essences, men's grooming items, sunscreens, and specialized body, hand, and foot care formulations. Maxigen Biotech Inc. was established in 1998 and operates from its main office in Taoyuan City, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.27% | -2.87% | -9.85% | -15.80% | -8.36% | -9.11% | -9.11% | -36.68% | +38.24% | +109.03% | +123.56% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+19.2% ★ Q1'26: +7.7% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+39.6% ★ Q1'26: +13.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+26.2% Q1'26: +28.2% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+32.2% ★ Q1'26: +30.6% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+29.8% ★ Q1'26: +23.6% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-0.1% ★ Q1'26: -1.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.35× ★ Q1'26: 0.43× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
261.47M
est: 338.00M (-22.6%)
|
427.68M
est: 459.00M (-6.8%)
|
452.20M
est: 450.00M (+0.5%)
|
457.69M
est: 474.00M (-3.4%)
|
680.65M
est: 338.00M (+101.4%)
|
811.56M
est: 459.00M (+76.8%)
|
459.00M
459.00M – 459.00M
+0.0% YoY
|
450.00M
450.00M – 450.00M
-2.0% YoY
|
474.00M
474.00M – 474.00M
+5.3% YoY
|
| EBITDA |
-47.61M
est: 96.58M (-149.3%)
|
87.54M
est: 131.15M (-33.3%)
|
108.69M
est: 128.58M (-15.5%)
|
110.08M
est: 135.44M (-18.7%)
|
221.40M
est: 104.74M (+111.4%)
|
293.18M
est: 142.24M (+106.1%)
|
142.24M
142.24M – 142.24M
+0.0% YoY
|
139.45M
139.45M – 139.45M
-2.0% YoY
|
146.89M
146.89M – 146.89M
+5.3% YoY
|
| EBIT |
-59.80M
est: 78.35M (-176.3%)
|
61.32M
est: 106.40M (-42.4%)
|
76.23M
est: 104.31M (-26.9%)
|
76.99M
est: 109.88M (-29.9%)
|
194.38M
est: 88.73M (+119.1%)
|
261.04M
est: 120.50M (+116.6%)
|
120.50M
120.50M – 120.50M
+0.0% YoY
|
118.14M
118.14M – 118.14M
-2.0% YoY
|
124.44M
124.44M – 124.44M
+5.3% YoY
|
| Net Income |
-62.96M
est: 13.98M (-550.4%)
|
57.06M
est: 75.33M (-24.3%)
|
60.11M
est: 73.00M (-17.7%)
|
63.31M
est: 77.66M (-18.5%)
|
190.17M
est: 13.97M (+1,261.4%)
|
265.31M
est: 75.28M (+252.5%)
|
75.28M
75.28M – 75.28M
+0.0% YoY
|
72.95M
72.95M – 72.95M
-3.1% YoY
|
77.60M
77.60M – 77.60M
+6.4% YoY
|
| SGA |
103.31M
est: 80.33M (+28.6%)
|
85.77M
est: 109.09M (-21.4%)
|
84.92M
est: 106.95M (-20.6%)
|
84.36M
est: 112.65M (-25.1%)
|
176.98M
est: 82.57M (+114.3%)
|
176.48M
est: 112.13M (+57.4%)
|
112.13M
112.13M – 112.13M
+0.0% YoY
|
109.93M
109.93M – 109.93M
-2.0% YoY
|
115.79M
115.79M – 115.79M
+5.3% YoY
|
| EPS |
-0.81
est: 0.16 (-619.8%)
|
0.67
est: 0.84 (-20.2%)
|
0.75
est: 0.81 (-7.8%)
|
0.79
est: 0.87 (-8.8%)
|
2.13
est: 0.16 (+1,266.8%)
|
2.96
est: 0.84 (+252.5%)
|
0.84
0.84 – 0.84
+0.0% YoY
|
0.81
0.81 – 0.81
-3.1% YoY
|
0.87
0.87 – 0.87
+6.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 72.3K | 0.39% |
| 2 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 45.5K | 0.28% |
| 3 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 18.6K | 0.29% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ching-Ting Chen | GM & Representative Director | 6M | female |
| Hao-Jun Wang | Supervisor of the Preci-sion Manufacturing Center | 2M | male |
| Ruei Yi Wu | Financial Officer & Accounting Officer | 2M | male |
| Karen Lee | Senior Manager of Administration | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1783.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
